Overcoming the Low Success Rate of New CNS Therapeutics

Jan. 11, 2011 - PRLog -- The discovery and development of drugs to treat conditions affecting the central nervous system (CNS) continues to be fraught with challenges and difficulties. One of the major factors restricting effective development is an incomplete knowledge of aetiology and pathophysiology of CNS disorders, including the dementias, neuropathic pain, mood disorders and the psychoses. There are a number of other factors that are affecting CNS advances; poor predictive validity of animal models, difficulty achieving an acceptable risk/benefit ratio and poor bioavailibity.

Recent failures and the stunted growth of CNS treatment hasn’t capped the interest in this area, the commercial size and huge unmet need for such methods ensures interest levels remain intense. Developing effective, risk-free drugs to treat such conditions will be immensely beneficial for sufferers across the globe.

SMi’s masterclass led by industry experts dedicated to making such advance look at a number of reasons why efforts may have been restricted. A thorough insight into factors that need considering when designing an effective research project programme will be a focus of this session, eliminating any problems within individuals research & Development efforts. Another focus will be improving the success rates so the risk/benefit ratio for applicable antidotes reaches an acceptable level by illustrating potential risk factors and discussing how to overcome them. The regulatory environment for CNS medicine research will also be addressed to ensure everyone has a collated understanding of what is deemed to be acceptable.

SMi masterclasses offer valuable information on a number of developing issues within the pharmaceutical industry, they also provide a brilliant platform to meet likeminded industry experts and expand your contact base.

For further information and the opportunity to register online please visit http://www.smi-online.co.uk/cns-therapeutics4.asp

# # #

SMi have had an established portfolio of Pharmaceutical, Defence, Energy, Finance and PPP/PFI events running since 1993. We are at the forefront of linking businesses with information, organising over 150 Conferences, Workshops and Masterclasses every year. All our events are research driven and highly targeted towards senior level professionals, designed to help you make informed decisions and remain at the cutting edge of business information.